This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

David L. Macdonald Appointed CEO Of GeneLink BioSciences, Inc.

ORLANDO, Fla., Dec. 28 /PRNewswire-FirstCall/ -- GeneLink BioSciences, Inc., (OTC Bulletin Board: GNLK) a leading consumer genomics and biotechnology company ( www.genelinkbio.com), is pleased to announce the appointment of David L. Macdonald as its interim Chief Executive Officer, effective December 28, 2009.  

Mr. Macdonald is a proven entrepreneurial leader with more than 25 years of experience building high performance teams and achieving aggressive goals in technical product and service environments.  He will be applying his skills, which are reflected by an impressive track record in the successful commercialization of proprietary healthcare related technology, international expansion, operational excellence, regulatory compliance, product development and execution of licensing opportunities.  Mr. Macdonald will help GeneLink develop and execute its plan to exploit its position as a scientific leader in consumer genomics.  

Prior to joining GeneLink, Mr. Macdonald served as the President and Chief Operating Officer at Nichols Institute Diagnostics (NID).  Upon acquisition of NID by Corning Life Sciences and the eventual spinout of Quest Diagnostics, Mr. Macdonald became a Vice President at Quest where, along with having responsibility for NID, he was a senior team member of Quest – a $5 billion laboratory services business with 30,000 employees.  He also served as CEO and Director at AltheaDx, CEO, President and Director at Nanomix, Senior Vice President of Global Operations and Business Development at Nanogen, and as CEO, President and a member of the Board of Directors at Progeny Systems.

Monte E. Taylor, Jr., who has served as the CEO of both GeneLink and its wholly owned subsidiary GeneWize, will continue as the CEO of GeneWize.  Bernard L. Kasten, MD, GeneLink's Executive Chairman reflected, "We wish to acknowledge that the success that GeneWize has enjoyed is largely due to the tireless efforts of Monte Taylor.  By developing an enhanced infrastructure at GeneLink to support GeneWize, Mr. Taylor will be able to focus his efforts toward growing GeneWize.  GeneLink, led by Mr. Macdonald, is committed to supporting Mr. Taylor, his GeneWize management team, our marketing affiliates and our customers."

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7870 -13.6380 -0.30%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs